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Purpose: The objective of this study was to formulate and optimize an orodispersible 
formulation of meloxicam using a 2
2
 factorial design for enhanced bioavailability. 
Methods: The tablets were made by non-aqueous wet granulation using crospovidone and 
mannitol. A 2
2
 factorial design was used to investigate the amount of crospovidone and taste 
masking, soothening hydrophilic agent (mannitol), as independent variables, and 
disintegration time as dependent response. Formulated orodispersible tablets were evaluated 
for weight variation, friability, disintegration time, drug content, wetting time, water absorption 
ratio and in vitro drug release.  
Results: The results show that the presence of a superdisintegrant and mannitol is desirable 
for orodispersion. All the formulations satisfied the limits of orodispersion with a dispersion 
time of less than 60 sec. For example, formulation F4 showed a disintegration time of 32.1 
sec, crushing strength of 4.93 kg/cm
2
, drug content of 98.5% and fast drug release rate of 
99.5% within 30 min, as compared with the conventional tablet (49.5%)  .  
Conclusion: It is feasible to formulate orodispersible tablets of meloxican with acceptable 
disintegration time, rapid drug release and good hardness, which could be amenable to 
replication on an industrial scale.  
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Introduction 
 
Difficulty in swallowing is a common problem 
of all age groups, especially geriatric and 
pediatric patients, due to physiological 
changes associated with these groups. These 
problems can be solved by development of a 
novel type of solid dosage form, namely, 
orodispersible tablet, which disintegrates and 
dissolves rapidly in saliva without the need of 
swallowing with drinking water since the tablet 





Clinically, nonsteroidal anti-inflammatory 
drugs (NSAIDs) are the most frequently 
prescribed by physicians for inflammatory 
disorders. Meloxicam [4-hydroxy-2methyl-N-
(5-methyl-2-thiazolyl)-2H-1,2-benzothiazine-3-
carboxamide1,1-dioxide], a nonsteroidal anti-
inflammatory drug, was chosen as a model 
drug for this study. It is one of the most 
commonly prescribed NSAIDs for the 
treatment of various inflammatory conditions 
such as rheumatoid arthritis, osteoarthritis, 
low back pain
3
. Although, it has excellent 
bioavailability (89%)
4
, its poor aqueous 
solubility
5
 makes absorption and dissolution 
rate-limited, thus delaying onset of action. 
Consequently, an orodispersible formulation 
of meloxicam was developed that could 
enhance the bioavailability and extent of 






Meloxicam was obtained from Siemen 
Laboratories, Haryana, India while  
Crosspovidone
 
was supplied by Signet 
Chemicals, Mumbai, India. Mannitol, colloidal 
silicone dioxide and spray dried lactose were 
obtained from Ranbaxy Fine Chemicals Ltd, 
New Delhi, India. Sodium saccharine and 
magnesium stearate were obtained from S.D. 
Fine Chemicals, Mumbai, India. All other  










was implemented for 
the optimization of meloxicam orodispersible 
tablet. The dependent response measured 
was disintegration time. Two independent 
factors - the concentration of crospovidone 
and concentration of mannitol - were set at 
two different levels. High and low levels of 
each factor were coded +1 and –1, 
respectively (Table 1). 
 
Table 1: Experimental design 2
2
 used for 



















Preparation of meloxicam tablets  
 
Orodispersible tablets of meloxicam were 
prepared as per the formula given in Table 2. 
Accurately weighed quantities of meloxicam, 
mannitol, crospovidone and other excipients 
were passed through sieve number 10 (as per 
Indian Pharmacopoeia)
7
 and mixed in a glass 
mortar. The above blend was granulated with 
a non-aqueous granulating agent, alcoholic 
solution of PVP (10%w/v), and passed 
through a sieve of aperture size, 710 µm. The 
granules were air-dried, mixed with 2%w/w 
colloidal silicone dioxide, and the granules 
were passed through sieve number 22, (as 
per Indian Pharmacopoeia)
7
 lubricated with 
magnesium stearate and compressed using 
CADMACH SMS25 single punch tablet 
machine at a fixed compression force of 400 
kgf . The mean weight and diameter of the 
tablets were 100mg and 8mm, respectively. 
 
Evaluation of orodispersible tablet 
 
All the tablets were evaluated for the following 
parameters: 
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Colloidal silicone dioxide 
Magnesium stearate 


































Twenty tablets were randomly selected from 
each batch and individually weighed. The 







 was measured using a 
ROCHE friabilator (USP) at 25 rpm for 4 min. 
The weight of twenty tablets  before and after 
completion of the test was recorded and 
friability was calculated by the following 
formula: 
Percentage friability= (initial weight-final 
weight/initial weight)×100 ………………      (1) 
 
Disintegration time  
 
Three tablets per batch were evaluated for 
disintegration time by employing a modified 
dissolution apparatus
9
. Instead of the 
disintegration apparatus described in JP XII, a 
modified dissolution apparatus (JP XII paddle 
method) was employed. Water (900 ml), 
maintained at 37±0.5 
0
C was stirred with a 
paddle at 100 rpm. Disintegration time was 
recorded when all the fragments of the 
disintegrated tablet passed through the screen 
of the basket.  
 
Crushing strength 
Tablet crushing strength, which is the force 
required to break the tablet, was measured 
with a Pfizer tablet hardness tester. The 
hardness (crushing strength) of three tablets 
per batch was determined and mean taken.   
 
Percentage drug content  
 
Drug content was determined by taking 
randomly ten tablets per batch. An amount 
equivalent to 10 mg meloxicam was dissolved 
in methanol, suitably diluted with 0.1N HCL 
and filtered. The absorbance of the solution 
was measured spectrophotometrically against 




Japan)   
 
Kinetic digital images 
 
One tablet of the selected formulation was 
placed in a glass full of water (see Figure 1) 
and the dispersion process was recorded, 
without agitation, and kinetic digital images 
were taken with a 7.2 mega pixel camera 
(Sony- DSC-W55, Japan). 
 
Wetting time and water absorption ratio  
 
The wetting time of the tablet was measured 
by placing five circular tissue papers (10 cm in 
diameter) in a Petri dish of 10 cm diameter. 
Water (10 ml) containing methylene blue 
(0.1% w/v) was added to the Petri dish. A 
tablet was carefully placed on the surface of 
the tissue paper and the time required for the 
dye to reach the upper surface of the tablet 
was recorded as wetting time. The measure-
ments  were  carried  out  in  triplicate.  Water  
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Figure 1: Sequential disintegration of orodisper-
sible tablets of meloxicam (A = 0 sec; B = 5 sec; C 
= 10sec; D = 15sec; E = 20 sec; F = 25 sec; G = 30 
sec; H = 40 sec) 
 
 




Water absorption ratio = (Wa –Wb)/ Wb    …..  (2)                                                   
  
where Wb = weight of tablet before absorption 
of water , and Wa = weight of tablet after 
absorption of water. 
 
In vitro drug release 
 
In vitro drug release studies were carried out 
using USP type II apparatus at 50 rpm. 
Phosphate buffer (900 ml) at pH 6.41 
(corresponding to salivary pH) was used as 
the dissolution medium. The temperature of 
the dissolution medium was maintained at 37 
±0.5 
0
C. An aliqout (5 ml) of dissolution 
medium was withdrawn at specific time 
intervals, filtered and suitably diluted prior to 
spectrophotometric analysis. Sink conditions 
were maintained by replenishing the medium 
with an equal amount (5 ml) of dissolution 
fluid. Absorption of the solution was measured 
by UV spectroscopy (Shimadzu-1700, Japan) 
at 354 nm. Dissolution rate was evaluated for 
all the formulations (F1-F4) and the 
conventional tablet. 
 
Validation of the experimental design  
 
In order to validate the experimental design 
using polynomial equation, disintegration time 
was selected. A two-level experimental design 
provides sufficient data to fit a polynomial 
equation
11
 (Eq. 3) which is in the following 
form: 
 
          )X(XBXB XB B y  211222110 +++= ……(3) 
 
where y represents the experimental 
response, B0 the intercept and  B1 to B12 are 
the coefficients for the factors X1 
(crospovidone) and X2 (mannitol). Students t- 
test was employed to examine the probability 
of each coefficient being equal to zero. All 
tests were performed at a 95% confidence 
level (P>0.05). In the final model equation, 
only the significant factors were included. The 
polynomial equation was applied to the 
response parameter, disintegration time, using 




The results of the measurements of various 
tablet parameters are tabulated in Table 3. 
 
Weight variation and friability 
 
The weight range was 98 - 99mg for all the 
tablets. This complies with Indian  
Pharmacopoeia
12
 specifications for uniformity 
of weight, thus indicating consistency in the 
preparation of the tablets and minimal batch to 
batch variation. The India Pharmacopoeia 
prescribes a friability <1% for good 
mechanical resistance. All the tablet 
formulations satisfied this requirement as 
friability was in the range of 0.51 - 0.69%   
 
Disintegration time  
 
All the formulations complied with the 
dispersion time requirement of ≤60 sec for 
orodispersible tablets as per European 
Pharmacopoeia
13
. Formulation F4 had the 
least dispersion time of 32.1 sec (Table 3). 
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Table 3: Physical properties of orodispersible tablets of meloxicam 
 
                                   Formulation Parameter* 
    F1      F2     F3       F4 
Weight Variation (mg) 98 ± 0.0 99 ± 1.3 99 ± 0.8 98 ± 0.9 
Friability (%) 0.7 0.6 0.7 0.5 
Disintegration time (sec) 33.0±1.4 34.5±0.8 34.8±1.5 32.1±1.1 
Crushing strength (kg/sqcm) 4.54±1.1 4.8±0.1 4.32±0.5 4.9±0.6 
Drug content (%) 97.9 97.1 98.8 98.5 
Wetting time (sec) 6.9 7.5 7.0 5.2 
Water absorption ratio 1.1 1.0 0.9 1.5 




The hardness of the formulated tablets was in 
the range of 4.54 - 4.93 kg/cm
2
 and did not 
show any significant difference among the 
various formulations.  
 
Wetting time and water absorption ratio 
 
The wetting time of all the tablet formulations 
was within the range of 5.15-7.50 sec and this 
indicates rapid absorption of water by the 
tablets due to the wicking action of 
crosspovidone. The water absorption of 
formulation F4 was highest with a value of 1.5, 
indicating a high amount of water uptake due 
to the high concentration of the independent 
factors.  
 
In vitro drug release 
 
All the formulations showed optimized drug 
release, with 98%-99% of the drug released 
within 30 min.  
 
Validation of the experimental design 
 
The theoretical response obtained from the 
polynomial equation at Y50% was found to be 
37.22sec and the experimental response of 
the extra design point formulation was found 
to be 34.6sec±0.43 which was quite close to 




Since mannitol has good aqueous solubility, 
negative heats of solution and good wetting 
properties, these attributes improve the 
binding of the tablets and water uptake, 
thereby decreasing disintegration time. All the 
formulations disintegrated in less than 60 sec. 
Formulation F4 demonstrated a minimum 
dispersion time of 32.1 sec; in this formulation, 
mannitol (an orodispersion aid) and 
crosspovidone were at their highest levels. 
The in vitro disintegration behavior, without 
agitation, of formulation F4 indicate that 
complete dispersion was obtained within 40 
sec (Figure 1). The difference between this 
value and the disintegration time obtained by 
the previous method may be attributed to the 
agitation involved in the previous method. 
There was no significant difference (P<0.05) 
among the four tablet formulations (F1 – F4) in 
terms of their physicochemical properties – 
disintegration time, crushing strength, friability 
and wetting time – except for water absorption 
ratio where F4 clearly showed a higher value 
than the other tablet formulations. The 
crushing strength values of 4.54 - 4.93 kg/cm
2 
are satisfactory and may have been facilitated 
by the incorporation of 2%w/w colloidal silicon 
dioxide which improves the hardness of the 
tablets, since colloidal silicon dioxide is known 
to enhance the bonding property of 
excipients
14
. This also would have had a 
positive effect on the friability of the tablets as  
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Figure 2: Drug release profile of formulations F1 - F4 and conventional meloxicam tablet in phosphate 
buffer (pH 6.41). (  F1;  F2; F3;  F4;  conventional meloxicam 
tablet)  
 
friability was within the limit of 1%. The water 
uptake ratio of F4 tablets was 1.521 times its 
actual weight, thus facilitating the process of 
orodispersion. 
 
All the formulations showed good drug release 
which was in the range, 98% - 99%, after 30 
min. Thus, incorporation of varying concen-
trations of crospovidone and mannitol did not 
significantly alter drug release (Figure 2). 
However, conventional meloxicam tablets 
exhibited approximately 50% of the release 
rate of the optimized tablets (F1 - F4). The 
formulation followed first order kinetics as a 
linear plot was obtained when log drug 
release was plotted against time. The 
correlation coefficient of the plot was 0.9792. 
The disintegration time data can be described 
by a model equation (Eq 4): 
Ydisintegration time =  28.91+1.21(X1) + 2.48(X2) 
+4.62(X1X2) ………………………………..  (4) 
The positive coefficient for equation X1 
indicates that a higher level of crosspovidone 
in the tablet formulation facilitated 
disintegration. The theoretical response at 
Y50% was 37.22sec while the experimental 
response of the extra design point formulation 
was 34.6sec±0.43 which was quite close to 





All the optimized tablet (orodispersible) 
formulations (F1 - F4) showed disintegration 
times that were less than 60 sec, as well as 
good physicochemical properties. Drug 
release rates of the orodispersable tablets 
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were much higher than that of the 
conventional tablets. The experimental design 
was also validated, as the theoretical 
response obtained correlated well with the 
practical response. The results indicate that 
the presence of crospovidone and mannitol 
not only enhanced the rate of orodispersion 
but also improved drug release rate. Thus, 
satisfactory orodispersible tablets of melo-
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